A recombinant sialidase enzyme derived from Vibrio cholera conjugated to trastuzumab (targeting HER2) was found to selectively desialylate HER2-positive breast cancer cells, thereby reducing ligands for binding by inhibitory siglecs-7 and -9 on NK cells. The gene discussed is ERBB2; the disease is breast carcinoma.